Venetoclax (VTC) is a selective BCL-2 inhibitor that directly targets the BCL-2 protein, modulating the mitochondrial apoptotic pathway and inducing tumor cell death (Li et al., 2019; Reddy et al., 2021). This evidence concerns the gene BCL2 and neoplasm.